glp·helper
glphelper.com/ozempic/pennsylvania/reading
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Reading, PA

Verified Ozempic providers in Reading, PA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
32
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Pennsylvania
33 of 33 shown

Find an Ozempic provider in Pennsylvania.

Every entry is checked against the NPI registry and the Pennsylvania medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Pennsylvania city · /ozempic/pennsylvania/{city}
§ 03Getting Ozempic in Reading
33 providers · Reading, PA

How to get Ozempic in Reading.

33 GLP-1 prescribers and 7 local resource types are on record for Reading, plus 3 nearby towns in the directory.

Prescribers in Reading
33 prescribers
33 GLP-1 prescribers in Reading, most listed as Family Medicine (14), Internal Medicine (13) and Internal Medicine, Endocrinology, Diabetes & Metabolism (4). Any Pennsylvania-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Lancaster (37 providers), Allentown (38 providers) and Norristown (27 providers).
Around the prescription in Reading
7 listed nearby
49 dietitians, 8 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 4 places to move are on record near Reading.
Medicaid (weight loss)
Diabetes only
As of April 2026, Pennsylvania Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Pennsylvania’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Reading

Reading, Pennsylvania has a population of 95,112 people. The adult obesity rate in Reading is an age-adjusted estimate of 43.3%, 9.1 percentage points above the Pennsylvania state rate of 34.2%. Diagnosed diabetes reaches 16.2% of adults in Reading. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 38.4% of adults in Reading.

of Reading adults have obesity
43.3%
diagnosed diabetes
16.2%
no regular physical activity
38.4%

Age-adjusted estimates for Reading, community figures, not individual risk. CDC PLACES, 2024 release.

Estimate your weight lossthe science of Ozempic face
§ 05Support around Ozempic in Reading
6 gyms

The prescription is one part. Here is the rest, in Reading.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Reading, PA, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

LA Fitness
GYM
4.4 on Google · 884 reviews
1183 Berkshire Blvd
Website
Body Zone Sports and Wellness Complex
GYM
4.6 on Google · 842 reviews
3103 Paper Mill Rd
Website
Planet Fitness
GYM
4.3 on Google · 769 reviews
3050 N 5th Street Hwy
Website
Planet Fitness
GYM
4.4 on Google · 501 reviews
510 E Lancaster Ave
Website
Retro Fitness
GYM
4.6 on Google · 470 reviews
700 Kenhorst Plaza
Website
Anytime Fitness
GYM
4.6 on Google · 141 reviews
1100 W Wyomissing Blvd
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Exeter Fitness and Training
FITNESS
4.8 on Google · 426 reviews
4270 Perkiomen Ave
Website
Wyo West Fitness
FITNESS
4.6 on Google · 349 reviews
1119 Bern Rd
Website
Wyomissing Fitness and Training
FITNESS
4.8 on Google · 325 reviews
950 Woodland Rd
Website
Reading YMCA
FITNESS
3.6 on Google · 103 reviews
631 Washington St
Website
Alliance Fitness Center - Spring Ridge
FITNESS
5.0 on Google · 77 reviews
1 Meridian Blvd
Website
Down Under Sports and Fitness
FITNESS
4.8 on Google · 60 reviews
31 Catherine St
Website
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Pennsylvania

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Pennsylvania

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]